It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing
Perhaps the best testament to Commissioner Hamburg's tenure is that crises were uniformly handled responsibly
In Jack Welch's view, one of the worst mistakes a manager can make is . . .
Are You Looking at ME?
Healthcare professionals' customer experiences are increasingly being shaped by retailers like Amazon and Zappos. What ideas should drugmakers borrow from them to personalize promotion and what are the limits?
The submissions to the MM&M Awards are closed and the fun—and the hours of work—have begun for our judges. As is the case every year, the 2015 panel is a group of esteemed leaders, thinkers and experts who represent a wide range of disciplines within pharma, biotech, devices and diagnostics, agencies and media companies. Their efforts will determine which agencies take home the gold on October 1 in New York City
Pharma companies have long struggled to pen compelling value stories for their products. Could they learn a thing or two from the case Keryx Pharmaceuticals built for its renal drug Auryxia? James Chase reports
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.